Results 11 to 20 of about 77,609 (253)

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C [PDF]

open access: yes, 2012
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Badenhoop, Klaus   +20 more
core   +14 more sources

Ribavirin

open access: yesThe Saudi Journal of Gastroenterology, 2001
Al Knawy Bandar
doaj   +2 more sources

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]

open access: yes, 2020
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula   +7 more
core   +1 more source

Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis

open access: yesAnnals of Hepatology, 2007
The aim of this study was to investigate the effects of combinations of pegilated–interferon (PEG–IFN), ribavirin, and danazol on thrombocytopenia and liver injury in rats with fibrosis.
Guillermo Cabrera Álvarez   +7 more
doaj   +1 more source

Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. [PDF]

open access: yesPLoS ONE, 2011
The nucleoside analogue Ribavirin significantly increases patient response to IFN-α treatment of HCV, by directly inhibiting viral replication. Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific
Nigel J Stevenson   +5 more
doaj   +1 more source

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. [PDF]

open access: yesPLoS ONE, 2013
Lethal mutagenesis, or virus extinction produced by enhanced mutation rates, is under investigation as an antiviral strategy that aims at counteracting the adaptive capacity of viral quasispecies, and avoiding selection of antiviral-escape mutants.
Ana M Ortega-Prieto   +8 more
doaj   +1 more source

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

open access: yes, 2019
Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y.   +2 more
core   +1 more source

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort [PDF]

open access: yes, 2016
BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings.
Abbas, Zaigham   +303 more
core   +1 more source

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]

open access: yes, 2017
Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero   +11 more
core   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

open access: yes, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy